{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:55:53Z","timestamp":1770454553891,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12185-020-02882-1","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T16:02:41Z","timestamp":1586793761000},"page":"418-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection"],"prefix":"10.1007","volume":"112","author":[{"given":"Sergio","family":"G\u00e1lvez Acosta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Javalera Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"issue":"2","key":"2882_CR1","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1002\/ajh.24971","volume":"93","author":"J Slostad","year":"2017","unstructured":"Slostad J, Hoversten P, Haddox C, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol. 2017;93(2):E47\u2013E4949. https:\/\/doi.org\/10.1002\/ajh.24971 (PMID 29134683).","journal-title":"Am J Hematol"},{"issue":"3","key":"2882_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","volume":"12","author":"J Sin","year":"2019","unstructured":"Sin J, Zangardi M. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther. 2019;12(3):166\u201370. https:\/\/doi.org\/10.1016\/j.hemonc.2017.07.002 (PMID 28834694).","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2882_CR3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471","author":"J Wang","year":"2019","unstructured":"Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, et al. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2019.222471 (PMID 31515353).","journal-title":"Haematologica"},{"issue":"19","key":"2882_CR4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"L Broglie","year":"2017","unstructured":"Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2017007526 (PMID 29296794).","journal-title":"Blood Adv"},{"key":"2882_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219878774","author":"T Trantham","year":"2019","unstructured":"Trantham T, Auten J, Muluneh B, Van Deventer H. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: a cautionary tale. J Oncol Pharm Pract. 2019. https:\/\/doi.org\/10.1177\/1078155219878774 (PMID 31575356).","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"2882_CR6","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1002\/ajh.25063","volume":"93","author":"I Zandvakili","year":"2018","unstructured":"Zandvakili I, Conboy CB, Ayed AO, et al. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol. 2018;93(5):E123\u2013E125125. https:\/\/doi.org\/10.1002\/ajh.25063 (PMID 29417621).","journal-title":"Am J Hematol"},{"issue":"12","key":"2882_CR7","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill S, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630\u2013e637637. https:\/\/doi.org\/10.1016\/S2352-3026(19)30156-5 (PMID 31537486).","journal-title":"Lancet Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02882-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02882-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T23:57:29Z","timestamp":1618271849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02882-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02882-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Their data or biological material.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants."}},{"value":"All procedures and treatment were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration. Hospital General Tijuana\u00b4s Research Bioethics Committee has confirmed that no ethical approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"In this case report, there is no patient identifying data or images. The patient signed informed consent for hospitalization and treatment. Hospital General Tijuana\u00b4s Research Bioethics Committee has confirmed that no further consent is required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}